Lung disease encompasses acute, infectious processes and chronic, non-infectious
processes such as chronic obstructive pulmonary disease, asthma and lung cancer. People …

Asthma affects over 300 million people worldwide and its prevalence is increasing. COPD is
the third leading cause of death globally. Asthma and COPD are complex inflammatory …

In recent years, personalized or precision medicine has made effective inroads into the
management of diseases, including respiratory diseases. The route to implementing this …

Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

The use of inhaled corticosteroids (ICS) in patients with bronchiectasis is a matter of debate
[1]. International registries report up to 42% of bronchiectasis patients receiving ICS …

Background Oxidative stress and persistent airway inflammation are thought to be important
contributors to the development of chronic obstructive pulmonary disease (COPD). This …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent
respiratory symptoms and dyspnea, as well as an increase in the number of leukocytes in …

Background The effect of inhaled corticosteroid (ICS) on the risk of severe acute respiratory
syndrome coronavirus 2 (SARS-COV-2) infection is unclear. Methods We performed a …

Blood eosinophils are a potentially useful biomarker for guiding inhaled corticosteroid (ICS)
treatment decisions in COPD. We investigated whether existing blood eosinophil counts …